Tempus AI (TEM) Stock Price, News & Analysis

Company Overview

Tempus AI is a technology company specializing in the application of artificial intelligence and data science to advance precision medicine. The firm operates a cloud-based analytics platform designed to aggregate and interpret clinical and molecular data, with a particular emphasis on oncology. By leveraging machine learning algorithms, Tempus AI aims to provide healthcare professionals with actionable insights that can inform treatment decisions and improve patient outcomes.

The company’s suite of services includes comprehensive genomic profiling, digital pathology analysis and liquid biopsy testing. These services are integrated into its proprietary software platform, which allows clinicians and researchers to access standardized data sets, analytic tools and real-time reporting. Tempus AI also offers customized solutions for pharmaceutical and biotech partners, supporting drug discovery, clinical trial design and biomarker identification through advanced data modeling.

Tempus AI collaborates with a broad range of institutions, including academic medical centers, community hospitals and research organizations across North America, Europe and select markets in Asia. Its partnerships extend to pharmaceutical companies seeking to accelerate therapeutic development and to health systems aiming to streamline precision medicine workflows. The company’s global operations are supported by regional teams that focus on regulatory compliance, data governance and technical integration.

Founded in 2015 by entrepreneur Eric Lefkofsky, Tempus AI has grown from a Chicago-based start-up into a prominent player in healthcare technology. Lefkofsky serves as Chief Executive Officer, guiding strategic initiatives and fostering collaborations with industry and academic leaders. Under his leadership, the company has expanded its product offerings and invested in research partnerships to refine its AI models and broaden the application of precision oncology and other disease areas.

Key Stats

• Today's Range: $59.54 to $61.57
• 50-Day Range: $51.67 to $72.00
• 52-Week Range: $30.77 to $91.45
• Volume: 6.39 million shs
• Average Volume: 7.39 million shs
• Market Capitalization: $10.50 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $63.67
• Consensus Rating: Moderate Buy

Tempus AI Stock Analysis - MarketRank™

Tempus AI scored higher than 45% of companies evaluated by MarketBeat, and ranked 1804th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tempus AI has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 7 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tempus AI has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tempus AI are expected to grow in the coming year, from ($6.15) to ($1.33) per share.

Price to Book Value per Share Ratio

Tempus AI has a P/B Ratio of 173.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

21.36% of the float of Tempus AI has been sold short.

Short Interest Ratio / Days to Cover

Tempus AI has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempus AI has recently decreased by 8.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tempus AI does not currently pay a dividend.

Dividend Growth

Tempus AI does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

21.36% of the float of Tempus AI has been sold short.

Short Interest Ratio / Days to Cover

Tempus AI has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempus AI has recently decreased by 8.92%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.37

News Sentiment

Tempus AI has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 45 news articles for Tempus AI this week, compared to 17 articles on an average week.

Search Interest

Only 109 people have searched for TEM on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

MarketBeat Follows

59 people have added Tempus AI to their MarketBeat watchlist in the last 30 days. This is an increase of 23% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tempus AI insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,300,238.00 in company stock.

Percentage Held by Insiders

27.60% of the stock of Tempus AI is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 24.22% of the stock of Tempus AI is held by institutions.

TEM Stock Analysis - Frequently Asked Questions

How have TEM shares performed this year?

Tempus AI's stock was trading at $33.76 on January 1st, 2025. Since then, TEM shares have increased by 79.7% and is now trading at $60.65.

How were Tempus AI's earnings last quarter?

Tempus AI, Inc. (NASDAQ:TEM) issued its earnings results on Tuesday, May, 6th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.03. Tempus AI's revenue was up 75.4% compared to the same quarter last year.
Read the conference call transcript.

When did Tempus AI IPO?

Tempus AI (TEM) raised $411 million in an IPO on Friday, June 14th 2024. The company issued 11,100,000 shares at $37.00 per share.

How do I buy shares of Tempus AI?

Shares of TEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tempus AI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tempus AI investors own include AST SpaceMobile (ASTS), NVIDIA (NVDA), Broadcom (AVGO), Micron Technology (MU), Recursion Pharmaceuticals (RXRX), Genius Sports (GENI) and Super Micro Computer (SMCI).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Computer Software
• Current Symbol: NASDAQ:TEM
• Previous Symbol: NASDAQ:TEM
• CIK: 1717115
• Web: www.tempus.com
• Phone: 800-976-5448
• Fax: N/A
• Employees: 2,400
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $63.67
• High Stock Price Target: $75.00
• Low Stock Price Target: $48.00
• Potential Upside/Downside: +4.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.54
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$705.81 million
• Net Margins: -88.27%
• Pretax Margin: -93.23%
• Return on Equity: -533.21%
• Return on Assets: -66.19%

Debt

• Debt-to-Equity Ratio: 2.45
• Current Ratio: 1.71
• Quick Ratio: 1.56

Sales & Book Value

• Annual Sales: $693.40 million
• Price / Sales: 15.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 174.18

Miscellaneous

• Outstanding Shares: 173,120,000
• Free Float: 125,336,000
• Market Cap: $10.55 billion
• Optionable: N/A
• Beta: N/A